1
|
Schepsky A, Traustadottir GA, Joelsson JP, Ingthorsson S, Kricker J, Bergthorsson JT, Asbjarnarson A, Gudjonsson T, Nupponen N, Slipicevic A, Lehmann F, Gudjonsson T. Melflufen, a peptide-conjugated alkylator, is an efficient anti-neo-plastic drug in breast cancer cell lines. Cancer Med 2020; 9:6726-6738. [PMID: 32717133 PMCID: PMC7520280 DOI: 10.1002/cam4.3300] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 06/10/2020] [Accepted: 06/24/2020] [Indexed: 12/11/2022] Open
Abstract
Melphalan flufenamide (hereinafter referred to as “melflufen”) is a peptide‐conjugated drug currently in phase 3 trials for the treatment of relapsed or refractory multiple myeloma. Due to its lipophilic nature, it readily enters cells, where it is converted to the known alkylator melphalan leading to enrichment of hydrophilic alkylator payloads. Here, we have analysed in vitro and in vivo the efficacy of melflufen on normal and cancerous breast epithelial lines. D492 is a normal‐derived nontumorigenic epithelial progenitor cell line whereas D492HER2 is a tumorigenic version of D492, overexpressing the HER2 oncogene. In addition we used triple negative breast cancer cell line MDA‐MB231. The tumorigenic D492HER2 and MDA‐MB231 cells were more sensitive than normal‐derived D492 cells when treated with melflufen. Compared to the commonly used anti‐cancer drug doxorubicin, melflufen was significantly more effective in reducing cell viability in vitro while it showed comparable effects in vivo. However, melflufen was more efficient in inhibiting metastasis of MDA‐MB231 cells. Melflufen induced DNA damage was confirmed by the expression of the DNA damage proteins ƴH2Ax and 53BP1. The effect of melflufen on D492HER2 was attenuated if cells were pretreated with the aminopeptidase inhibitor bestatin, which is consistent with previous reports demonstrating the importance of aminopeptidase CD13 in facilitating melflufen cleavage. Moreover, analysis of CD13high and CD13low subpopulations of D492HER2 cells and knockdown of CD13 showed that melflufen efficacy is mediated at least in part by CD13. Knockdown of LAP3 and DPP7 aminopeptidases led to similar efficacy reduction, suggesting that also other aminopeptidases may facilitate melflufen conversion. In summary, we have shown that melflufen is a highly efficient anti‐neoplastic agent in breast cancer cell lines and its efficacy is facilitated by aminopeptidases.
Collapse
Affiliation(s)
- Alexander Schepsky
- Stem Cell Research Unit, Biomedical Center, University of Iceland, Reykjavik, Iceland
| | | | - Jon Petur Joelsson
- Stem Cell Research Unit, Biomedical Center, University of Iceland, Reykjavik, Iceland
| | - Saevar Ingthorsson
- Stem Cell Research Unit, Biomedical Center, University of Iceland, Reykjavik, Iceland
| | - Jennifer Kricker
- Stem Cell Research Unit, Biomedical Center, University of Iceland, Reykjavik, Iceland
| | - Jon Thor Bergthorsson
- Department of Laboratory Hematology, University Hospital, Landspitali, Reykjavik, Iceland
| | - Arni Asbjarnarson
- Stem Cell Research Unit, Biomedical Center, University of Iceland, Reykjavik, Iceland
| | | | | | | | | | - Thorarinn Gudjonsson
- Stem Cell Research Unit, Biomedical Center, University of Iceland, Reykjavik, Iceland.,Department of Laboratory Hematology, University Hospital, Landspitali, Reykjavik, Iceland
| |
Collapse
|
2
|
Abstract
Since the introduction of the cancer stem cell (CSC) hypothesis, accumulating evidence shows that most cancers present stem-like niches. However, therapies aimed at targeting this niche have not been as successful as expected. New evidence regarding CSCs hierarchy, similarities with normal tissue stem cells and cell plasticity might be key in understanding their role in cancer biology and how to efficiently eliminate them. In this Chapter, we discuss what is known in breast and prostate CSCs from their initial discoveries to the current therapeutic efforts in the field. Future challenges towards better CSC identification and isolation strategies will be key to shed light into how CSCs could accurately be targeted in combination to traditional therapies to ultimately prolong patient survival.
Collapse
Affiliation(s)
- Rocío G Sampayo
- Department of Chemical and Biomolecular Engineering, University of California at Berkeley, Berkeley, CA, United States
| | - Mina J Bissell
- Division of Biological Systems and Engineering, Lawrence Berkeley National Laboratory, Berkeley, CA, United States.
| |
Collapse
|
3
|
Briem E, Ingthorsson S, Traustadottir GA, Hilmarsdottir B, Gudjonsson T. Application of the D492 Cell Lines to Explore Breast Morphogenesis, EMT and Cancer Progression in 3D Culture. J Mammary Gland Biol Neoplasia 2019; 24:139-147. [PMID: 30684066 DOI: 10.1007/s10911-018-09424-w] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2018] [Accepted: 12/21/2018] [Indexed: 12/19/2022] Open
Abstract
The human female breast gland is composed of branching epithelial ducts that extend from the nipple towards the terminal duct lobular units (TDLUs), which are the functional, milk-producing units of the gland and the site of origin of most breast cancers. The epithelium of ducts and TDLUs is composed of an inner layer of polarized luminal epithelial cells and an outer layer of contractile myoepithelial cells, separated from the vascular-rich stroma by a basement membrane. The luminal- and myoepithelial cells share an origin and in recent years, there has been increasing understanding of how these cell types interact and how they contribute to breast cancer. Accumulating evidence links stem/or progenitor cells in the mammary/breast gland to breast cancer. In that regard, much knowledge has been gained from studies in mice due to specific strains that have allowed for gene knock out/in studies and lineage tracing of cellular fates. However, there is a large histologic difference between the human female breast gland and the mouse mammary gland that necessitates that research needs to be done on human material where primary cultures are important due to their close relation to the tissue of origin. However, due to difficulties of long-term cultures and lack of access to material, human cell lines are of great importance to bridge the gap between studies on mouse mammary gland and human primary breast cells. In this review, we describe D492, a breast epithelial progenitor cell line that can generate both luminal- and myoepithelial cells in culture, and in 3D culture it forms branching ducts similar to TDLUs. We have applied D492 and its daughter cell lines to explore cellular and molecular mechanisms of branching morphogenesis and cellular plasticity including EMT and MET. In addition to discussing the application of D492 in studying normal morphogenesis, we will also discuss how this cell line has been used to study breast cancer progression.
Collapse
Affiliation(s)
- Eirikur Briem
- Stem Cell Research Unit, Biomedical Center, Department of Anatomy, Faculty of Medicine, School of Health Sciences, University of Iceland, Vatnsmyrarvegi 16, 101, Reykjavík, Iceland
| | - Saevar Ingthorsson
- Stem Cell Research Unit, Biomedical Center, Department of Anatomy, Faculty of Medicine, School of Health Sciences, University of Iceland, Vatnsmyrarvegi 16, 101, Reykjavík, Iceland
| | - Gunnhildur Asta Traustadottir
- Stem Cell Research Unit, Biomedical Center, Department of Anatomy, Faculty of Medicine, School of Health Sciences, University of Iceland, Vatnsmyrarvegi 16, 101, Reykjavík, Iceland
| | - Bylgja Hilmarsdottir
- Department of Tumor Biology, The Norwegian Radium Hospital, Oslo, Norway
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Thorarinn Gudjonsson
- Stem Cell Research Unit, Biomedical Center, Department of Anatomy, Faculty of Medicine, School of Health Sciences, University of Iceland, Vatnsmyrarvegi 16, 101, Reykjavík, Iceland.
- Department of Laboratory Hematology, Landspitali - University Hospital, Reykjavík, Iceland.
| |
Collapse
|
4
|
Kim J, Villadsen R. Expression of Luminal Progenitor Marker CD117 in the Human Breast Gland. J Histochem Cytochem 2018; 66:879-888. [PMID: 30004288 DOI: 10.1369/0022155418788845] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
CD117 is a putative marker of luminal progenitor cells in the human breast. However, so far mapping the expression pattern of CD117 within the normal gland has not been reported. Here, we examined the anatomical distribution of CD117-expressing cells in lobular and ductal structures by immunohistochemistry. The presence of CD117-positive luminal cells could be divided into three distinct patterns: (1) contiguous, with coherent positive cells and rare negative cells interspaced; (2) patched, with a roughly equal frequency of positive and negative cells distributed focally; or (3) scattered, with few or no positive cells in the structure. Generally, a patched or scattered expression pattern was more frequent in lobules compared with ducts. Furthermore, an age-correlated increase in heterogeneity was observed. When comparing women below and above 21 years of age this heterogeneity was evident for both lobules and ducts. Although CD117-expression was generally segregated from luminal-lineage transcription factor GATA3-positive cells, some did co-express both markers. Finally, co-staining with Ki-67 revealed that a prominent part of cycling cells belonged to the CD117-positive population. Together these data demonstrate the presence of a CD117-expressing progenitor compartment with the capacity to replenish the luminal lineage of the breast gland.
Collapse
Affiliation(s)
- Jiyoung Kim
- Department of Cellular and Molecular Medicine, and Novo Nordisk Center for Stem Cell Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - René Villadsen
- Department of Cellular and Molecular Medicine, and Novo Nordisk Center for Stem Cell Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
5
|
Makarenkova HP, Dartt DA. Myoepithelial Cells: Their Origin and Function in Lacrimal Gland Morphogenesis, Homeostasis, and Repair. CURRENT MOLECULAR BIOLOGY REPORTS 2015; 1:115-123. [PMID: 26688786 PMCID: PMC4683023 DOI: 10.1007/s40610-015-0020-4] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Lacrimal gland (LG) is an exocrine tubuloacinar gland that secretes the aqueous layer of the tear film. LG epithelium is composed of ductal, acinar, and myoepithelial cells (MECs) bordering the basal lamina and separating the epithelial layer from the extracellular matrix. Mature MECs have contractile ability and morphologically resemble smooth muscle cells; however, they exhibit features typical for epithelial cells, such as the presence of specific cytokeratin filaments. Increasing evidence supports the assertion that myoepithelial cells (MECs) play key roles in the lacrimal gland development, homeostasis, and stabilizing the normal structure and polarity of LG secretory acini. MECs take part in the formation of extracellular matrix gland and participate in signal exchange between epithelium and stroma. MECs have a high level of plasticity and are able to differentiate into several cell lineages. Here, we provide a review on some of the MEC characteristics and their role in LG morphogenesis, maintenance, and repair.
Collapse
Affiliation(s)
- Helen P. Makarenkova
- Department of Cell and Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Darlene A. Dartt
- Schepens Eye Research Institute/Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
6
|
Amy D, Durante E, Tot T. The lobar approach to breast ultrasound imaging and surgery. J Med Ultrason (2001) 2015; 42:331-9. [DOI: 10.1007/s10396-015-0625-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Accepted: 03/04/2015] [Indexed: 11/28/2022]
|
7
|
Balk-Møller E, Kim J, Hopkinson B, Timmermans-Wielenga V, Petersen OW, Villadsen R. A marker of endocrine receptor-positive cells, CEACAM6, is shared by two major classes of breast cancer: luminal and HER2-enriched. THE AMERICAN JOURNAL OF PATHOLOGY 2014; 184:1198-208. [PMID: 24655379 DOI: 10.1016/j.ajpath.2013.12.013] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Received: 06/20/2013] [Revised: 12/11/2013] [Accepted: 12/12/2013] [Indexed: 12/19/2022]
Abstract
Elucidating the phenotypic evolution of breast cancer through distinct subtypes relies heavily on defining a lineage blueprint of the normal human breast. Here, we show that in normal breast, within the luminal epithelial lineage, a subset of cells characterized by strong staining for endocrine receptors are also characterized by expression of the surface marker CEACAM6. Topographically, this pattern of staining predominates in terminal ductal lobular units, rather than in interlobular ducts. In culture, CEACAM6-expressing cells remain essentially postmitotic under conditions in which the other cells of luminal epithelial lineage are highly proliferative. We examined the pattern of expression among three major breast cancer subtypes: luminal, HER2-enriched, and basal-like. In 104 biopsies, the luminal and HER2-enriched subtypes showed a high proportion of CEACAM6(+) tumors (78% and 83%, respectively); the basal-like subtype showed a low proportion (28%). Further accentuation of this pattern was observed in 13 established breast cancer cell lines. When differentiation was induced by all-trans retinoic acid, CEACAM6 expression strongly correlated with luminal-like differentiation. Furthermore, CEACAM6(+) cancer cells were less proliferative than CEACAM6(-) cells in tumorsphere assays and were less tumorigenic in nude mice. Based on these observations, we propose that luminal and HER2-enriched breast cancers are more closely related than previously thought and may share a common cell of origin.
Collapse
Affiliation(s)
- Emilie Balk-Møller
- Department of Cellular and Molecular Medicine, the Panum Institute, the Center for Biological Disease Analysis, and the Danish Stem Cell Center, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Jiyoung Kim
- Department of Cellular and Molecular Medicine, the Panum Institute, the Center for Biological Disease Analysis, and the Danish Stem Cell Center, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Branden Hopkinson
- Department of Cellular and Molecular Medicine, the Panum Institute, the Center for Biological Disease Analysis, and the Danish Stem Cell Center, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
| | | | - Ole W Petersen
- Department of Cellular and Molecular Medicine, the Panum Institute, the Center for Biological Disease Analysis, and the Danish Stem Cell Center, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
| | - René Villadsen
- Department of Cellular and Molecular Medicine, the Panum Institute, the Center for Biological Disease Analysis, and the Danish Stem Cell Center, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
| |
Collapse
|
8
|
Figueroa JD, Pfeiffer RM, Patel DA, Linville L, Brinton LA, Gierach GL, Yang XR, Papathomas D, Visscher D, Mies C, Degnim AC, Anderson WF, Hewitt S, Khodr ZG, Clare SE, Storniolo AM, Sherman ME. Terminal duct lobular unit involution of the normal breast: implications for breast cancer etiology. J Natl Cancer Inst 2014; 106:dju286. [PMID: 25274491 DOI: 10.1093/jnci/dju286] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Greater degrees of terminal duct lobular unit (TDLU) involution have been linked to lower breast cancer risk; however, factors that influence this process are poorly characterized. METHODS To study this question, we developed three reproducible measures that are inversely associated with TDLU involution: TDLU counts, median TDLU span, and median acini counts/TDLU. We determined factors associated with TDLU involution using normal breast tissues from 1938 participants (1369 premenopausal and 569 postmenopausal) ages 18 to 75 years in the Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center. Multivariable zero-inflated Poisson models were used to estimate relative risks (RRs) and 95% confidence intervals (95% CIs) for factors associated with TDLU counts, and multivariable ordinal logistic regression models were used to estimate odds ratios (ORs) and 95% CIs for factors associated with categories of median TDLU span and acini counts/TDLU. RESULTS All TDLU measures started declining in the third age decade (all measures, two-sided P trend ≤ .001); and all metrics were statistically significantly lower among postmenopausal women. Nulliparous women demonstrated lower TDLU counts compared with uniparous women (among premenopausal women, RR = 0.79, 95% CI = 0.73 to 0.85; among postmenopausal, RR = 0.67, 95% CI = 0.56 to 0.79); however, rates of age-related TDLU decline were faster among parous women. Other factors were related to specific measures of TDLU involution. CONCLUSION Morphometric analysis of TDLU involution warrants further evaluation to understand the pathogenesis of breast cancer and assessing its role as a progression marker for women with benign biopsies or as an intermediate endpoint in prevention studies.
Collapse
Affiliation(s)
- Jonine D Figueroa
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS).
| | - Ruth M Pfeiffer
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| | - Deesha A Patel
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| | - Laura Linville
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| | - Louise A Brinton
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| | - Gretchen L Gierach
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| | - Xiaohong R Yang
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| | - Daphne Papathomas
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| | - Daniel Visscher
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| | - Carolyn Mies
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| | - Amy C Degnim
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| | - William F Anderson
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| | - Stephen Hewitt
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| | - Zeina G Khodr
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| | - Susan E Clare
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| | - Anna Maria Storniolo
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| | - Mark E Sherman
- Division of Cancer Epidemiology and Genetics (JDF, RMP, DAP, LL, LAB, GLG, XRY, DP, WFA, ZGK, MES), Laboratory of Pathology (SH), and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Mayo Clinic Cancer Center, Rochester, MN (DV, ACD); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA (CM); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (SEC); Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center, Indianapolis, IN (AMS)
| |
Collapse
|
9
|
|
10
|
Abstract
Much evidence now suggests that angiotensin II has roles in normal functions of the breast that may be altered or attenuated in cancer. Both angiotensin type 1 (AT1) and type 2 (AT2) receptors are present particularly in the secretory epithelium. Additionally, all the elements of a tissue renin-angiotensin system, angiotensinogen, prorenin and angiotensin-converting enzyme (ACE), are also present and distributed in different cell types in a manner suggesting a close relationship with sites of angiotensin II activity. These findings are consistent with the concept that stromal elements and myoepithelium are instrumental in maintaining normal epithelial structure and function. In disease, this system becomes disrupted, particularly in invasive carcinoma. Both AT1 and AT2 receptors are present in tumours and may be up-regulated in some. Experimentally, angiotensin II, acting via the AT1 receptor, increases tumour cell proliferation and angiogenesis, both these are inhibited by blocking its production or function. Epidemiological evidence on the effect of expression levels of ACE or the distribution of ACE or AT1 receptor variants in many types of cancer gives indirect support to these concepts. It is possible that there is a case for the therapeutic use of high doses of ACE inhibitors and AT1 receptor blockers in breast cancer, as there may be for AT2 receptor agonists, though this awaits full investigation. Attention is drawn to the possibility of blocking specific AT1-mediated intracellular signalling pathways, for example by AT1-directed antibodies, which exploit the possibility that the extracellular N-terminus of the AT1 receptor may have previously unsuspected signalling roles.
Collapse
Affiliation(s)
- Gavin P Vinson
- School of Biological and Chemical Sciences, Queen Mary University of London, London E1 4NS, UK.
| | | | | |
Collapse
|
11
|
Gökmen-Polar Y, Nakshatri H, Badve S. Biomarkers for breast cancer stem cells: the challenges ahead. Biomark Med 2011; 5:661-71. [DOI: 10.2217/bmm.11.57] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Recent studies suggest that a subset of cancer cells with the ability for self-renewal and differentiation into different cell lineages is responsible for tumor progression, metastasis and resistance therapy. These cells, designated as tumor-initiating cells, tumor-propagating cells or cancer stem cells, are of great interest for cancer prognostication and therapeutics. Numerous cell surface and intracellular markers exhibiting cancer stem cell characteristics have been identified in breast cancer, presenting a promise to use them as biomarkers. However, there is a great need for the improvement of experimental methods to detect them in clinical samples, and validate their utility as predictors of the disease outcome, propensity for metastasis and response to treatment. In this article, we present an overview of the current status of breast cancer stem cells, with a focus on biomarkers. We also discuss the technical challenges on the road to defining breast cancer stem cells as biomarkers.
Collapse
Affiliation(s)
- Yesim Gökmen-Polar
- Department of Medicine, Indiana University Simon Cancer Center, Indiana University, Indianapolis, IN 46202, USA
| | - Harikrishna Nakshatri
- Department of Surgery, Indiana University Simon Cancer Center, Indiana University, Indianapolis, IN 46202, USA
| | - Sunil Badve
- IU Health Pathology Laboratory, Department of Pathology, 350 West 11th Street, 4050, Indianapolis, IN 46202, USA
| |
Collapse
|
12
|
|
13
|
Eden JA. Breast cancer, stem cells and sex hormones: part 1. The impact of fetal life and infancy. Maturitas 2010; 67:117-20. [PMID: 20579822 DOI: 10.1016/j.maturitas.2010.05.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2010] [Revised: 05/12/2010] [Accepted: 05/13/2010] [Indexed: 01/27/2023]
Abstract
Like other organs, the breast contains rare somatic stem cells (SCs) that are long-lived and slowly dividing. In the adult breast, they are closely regulated in areas located along the breast ducts called SC niches. Breast SCs can produce offspring that become ductal, alveoli or myoepithelial cells. In fetal life, SCs form the primitive breast ducts and up to 30 weeks of gestational age, this process appears to be largely independent of estrogen. Early life risk factors for breast cancer include birth weight, rapid growth during infancy and diet. The impact of these risk factors may be mediated through SC number. These somatic breast SCs persist into adult life and so they are exposed to oncogenic influences for much longer than the short-lived differentiated breast ductal and alveolar cells. As such, it is likely that the breast SC is a prominent target for carcinogenesis and so SC number may be an important determinant of breast cancer risk later in life.
Collapse
Affiliation(s)
- John A Eden
- School of Women and Children's Health, Royal Hospital for Women, Barker Street, Randwick, NSW, 2031, Australia.
| |
Collapse
|
14
|
Abstract
Carcinomas may arise as a disorder of regeneration, so that a malignant cell may represent a failure to fully attain the characteristics of differentiated tissue. We hypothesized that there is a differential distribution of progenitor cell markers among different histological types of lung cancers, with poorly differentiated tumors being more likely to express progenitor stem cell markers. The study was limited to paraffin-embedded archival material of resected untreated pulmonary carcinomas, including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and small cell carcinoma. The sections were stained for putative stem cells markers (Musashi-1, Musashi-2, CD34, CD21, KIT, CD133, p63, and OCT-4). Positivity was read as isolated, focal, or diffuse staining. Stem cell markers were detected in all histological types of pulmonary carcinomas. There was a difference in the expression of markers among the histological types. Small cell carcinoma showed diffuse positivity for most of the markers; in contrast to focal or negative staining in other histological groups. An inverse relationship between CD21 and Musashi-1 was observed. No staining for OCT-4 and CD34 was seen in any of the tumor types. Hierarchical clustering based on marker expression separated tumors into two groups, with one group marked by high expression of Musashi-1 and KIT, contained most of the poorly differentiated adenocarcinomas and small cell carcinomas. Therefore, stem cell markers are expressed in lung cancers with different patterns seen for different histological types and degrees of differentiation.
Collapse
|
15
|
Honoki K. Do stem-like cells play a role in drug resistance of sarcomas? Expert Rev Anticancer Ther 2010; 10:261-70. [PMID: 20132001 DOI: 10.1586/era.09.184] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Stem cells are defined by their unique characteristics, which include their abilities to self-renew and differentiate. Normal somatic stem cells have been isolated from various tissues such as bone marrow, adipose tissue, mammary glands and the nervous system. They are considered naturally resistant to chemotherapeutic agents because they express high levels of membrane transporter molecules, detoxifying enzymes and DNA repair proteins. Several recent studies have identified the presence of side populations in various cancer tissues, the so-called 'cancer stem cells', which are defined as the counterparts of stem cells in tumor tissues. These cancer stem cells possess stem-like properties, such as self-renewal and differentiation abilities, as well as playing a role in tumor initiation. Most sarcomas, which are thought to originate from mesenchymal stem cells, are highly malignant and approximately 30-40% of them show local and/or distant relapse (metastasis), even in the case of relatively chemosensitive tumors such as osteosarcomas and Ewing sarcomas. Several studies have suggested the presence of stem-like cell populations in sarcomas, based on their tumorigenicity and drug resistance. This review explores the issues of drug resistance of cancer stem cells in sarcomas and the possibilities of targeting cancer stem cells for the future treatment of sarcomas.
Collapse
Affiliation(s)
- Kanya Honoki
- Department of Orthopedic Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.
| |
Collapse
|
16
|
|
17
|
De la cellule mammaire normale à la cellule cancéreuse. MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE 2010. [DOI: 10.1016/j.mednuc.2009.11.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
18
|
Meyer MJ, Fleming JM, Ali MA, Pesesky MW, Ginsburg E, Vonderhaar BK. Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res 2009; 11:R82. [PMID: 19906290 PMCID: PMC2815544 DOI: 10.1186/bcr2449] [Citation(s) in RCA: 114] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2009] [Revised: 10/21/2009] [Accepted: 11/11/2009] [Indexed: 03/02/2023] Open
Abstract
Introduction The invasive, mesenchymal phenotype of CD44posCD24neg breast cancer cells has made them a promising target for eliminating the metastatic capacity of primary tumors. It has been previously demonstrated that CD44neg/lowCD24pos breast cancer cells lack the ability to give rise to their invasive CD44posCD24neg counterpart. Here we demonstrate that noninvasive, epithelial-like CD44posCD24pos cells readily give rise to invasive, mesenchymal CD44posCD24neg progeny in vivo and in vitro. This interconversion was found to be dependent upon Activin/Nodal signaling. Methods Breast cancer cell lines were sorted into CD44posCD24pos and CD44posCD24neg populations to evaluate their progeny for the expression of CD44, CD24, and markers of a mesenchymal phenotype. The populations, separated by fluorescence activated cell sorting (FACS) were injected into immunocompromised mice to evaluate their tumorigenicity and invasiveness of the resulting xenografts. Results CD24 expression was dynamically regulated in vitro in all evaluated breast cancer cell lines. Furthermore, a single noninvasive, epithelial-like CD44posCD24pos cell had the ability to give rise to invasive, mesenchymal CD44posCD24neg progeny. Importantly, this interconversion occurred in vivo as CD44posCD24pos cells gave rise to xenografts with locally invasive borders as seen in xenografts initiated with CD44posCD24neg cells. Lastly, the ability of CD44posCD24pos cells to give rise to mesenchymal progeny, and vice versa, was blocked upon ablation of Activin/Nodal signaling. Conclusions Our data demonstrate that the invasive, mesenchymal CD44posCD24neg phenotype is under dynamic control in breast cancer cell lines both in vitro and in vivo. Furthermore, our observations suggest that therapies targeting CD44posCD24neg tumor cells may have limited success in preventing primary tumor metastasis unless Activin/Nodal signaling is arrested.
Collapse
Affiliation(s)
- Matthew J Meyer
- Mammary Biology and Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Building 37, Room 1106, Bethesda, Maryland 20892-4254, USA.
| | | | | | | | | | | |
Collapse
|
19
|
Dey D, Saxena M, Paranjape AN, Krishnan V, Giraddi R, Kumar MV, Mukherjee G, Rangarajan A. Phenotypic and functional characterization of human mammary stem/progenitor cells in long term culture. PLoS One 2009; 4:e5329. [PMID: 19390630 PMCID: PMC2669709 DOI: 10.1371/journal.pone.0005329] [Citation(s) in RCA: 87] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2008] [Accepted: 03/25/2009] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND Cancer stem cells exhibit close resemblance to normal stem cells in phenotype as well as function. Hence, studying normal stem cell behavior is important in understanding cancer pathogenesis. It has recently been shown that human breast stem cells can be enriched in suspension cultures as mammospheres. However, little is known about the behavior of these cells in long-term cultures. Since extensive self-renewal potential is the hallmark of stem cells, we undertook a detailed phenotypic and functional characterization of human mammospheres over long-term passages. METHODOLOGY Single cell suspensions derived from human breast 'organoids' were seeded in ultra low attachment plates in serum free media. Resulting primary mammospheres after a week (termed T1 mammospheres) were subjected to passaging every 7th day leading to the generation of T2, T3, and T4 mammospheres. PRINCIPAL FINDINGS We show that primary mammospheres contain a distinct side-population (SP) that displays a CD24(low)/CD44(low) phenotype, but fails to generate mammospheres. Instead, the mammosphere-initiating potential rests within the CD44(high)/CD24(low) cells, in keeping with the phenotype of breast cancer-initiating cells. In serial sphere formation assays we find that even though primary (T1) mammospheres show telomerase activity and fourth passage T4 spheres contain label-retaining cells, they fail to initiate new mammospheres beyond T5. With increasing passages, mammospheres showed an increase in smaller sized spheres, reduction in proliferation potential and sphere forming efficiency, and increased differentiation towards the myoepithelial lineage. Significantly, staining for senescence-associated beta-galactosidase activity revealed a dramatic increase in the number of senescent cells with passage, which might in part explain the inability to continuously generate mammospheres in culture. CONCLUSIONS Thus, the self-renewal potential of human breast stem cells is exhausted within five in vitro passages of mammospheres, suggesting the need for further improvisation in culture conditions for their long-term maintenance.
Collapse
Affiliation(s)
- Devaveena Dey
- Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India
| | - Meera Saxena
- Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India
| | - Anurag N. Paranjape
- Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India
| | - Visalakshi Krishnan
- Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India
| | - Rajashekhar Giraddi
- Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India
| | - M. Vijaya Kumar
- Department of Pathology, Kidwai Memorial Institute of Oncology, Bangalore, India
| | - Geetashree Mukherjee
- Department of Pathology, Kidwai Memorial Institute of Oncology, Bangalore, India
| | - Annapoorni Rangarajan
- Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India
| |
Collapse
|
20
|
Abstract
Breast cancer is a heterogeneous disease and classification is important for clinical management. At least five subtypes can be identified based on unique gene expression patterns; this subtype classification is distinct from the histopathological classification. The transcription factor network(s) required for the specific gene expression signature in each of these subtypes is currently being elucidated. The transcription factor network composed of the oestrogen (estrogen) receptor alpha (ERalpha), FOXA1 and GATA3 may control the gene expression pattern in luminal subtype A breast cancers. Breast cancers that are dependent on this network correspond to well-differentiated and hormone-therapy-responsive tumours with good prognosis. In this review, we discuss the interplay between these transcription factors with a particular emphasis on FOXA1 structure and function, and its ability to control ERalpha function. Additionally, we discuss modulators of FOXA1 function, ERalpha-FOXA1-GATA3 downstream targets, and potential therapeutic agents that may increase differentiation through FOXA1.
Collapse
|
21
|
Vydra J, Selicharová I, Smutná K, Šanda M, Matoušková E, Buršíková E, Prchalová M, Velenská Z, Coufal D, Jiráček J. Two-dimensional electrophoretic comparison of metastatic and non-metastatic human breast tumors using in vitro cultured epithelial cells derived from the cancer tissues. BMC Cancer 2008; 8:107. [PMID: 18416831 PMCID: PMC2377273 DOI: 10.1186/1471-2407-8-107] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2008] [Accepted: 04/16/2008] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Breast carcinomas represent a heterogeneous group of tumors diverse in behavior, outcome, and response to therapy. Identification of proteins resembling the tumor biology can improve the diagnosis, prediction, treatment selection, and targeting of therapy. Since the beginning of the post-genomic era, the focus of molecular biology gradually moved from genomes to proteins and proteomes and to their functionality. Proteomics can potentially capture dynamic changes in protein expression integrating both genetic and epigenetic influences. METHODS We prepared primary cultures of epithelial cells from 23 breast cancer tissue samples and performed comparative proteomic analysis. Seven patients developed distant metastases within three-year follow-up. These samples were included into a metastase-positive group, the others formed a metastase-negative group. Two-dimensional electrophoretical (2-DE) gels in pH range 4-7 were prepared. Spot densities in 2-DE protein maps were subjected to statistical analyses (R/maanova package) and data-mining analysis (GUHA). For identification of proteins in selected spots, liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed. RESULTS Three protein spots were significantly altered between the metastatic and non-metastatic groups. The correlations were proven at the 0.05 significance level. Nucleophosmin was increased in the group with metastases. The levels of 2,3-trans-enoyl-CoA isomerase and glutathione peroxidase 1 were decreased. CONCLUSION We have performed an extensive proteomic study of mammary epithelial cells from breast cancer patients. We have found differentially expressed proteins between the samples from metastase-positive and metastase-negative patient groups.
Collapse
Affiliation(s)
- Jan Vydra
- Department of Oncology, 1st Faculty of Medicine, Charles University Prague, Czech Republic
| | - Irena Selicharová
- Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | - Kateřina Smutná
- Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | - Miloslav Šanda
- Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | - Eva Matoušková
- Institute of Biochemistry and Experimental Oncology, 1st Faculty of Medicine, Charles University Prague, Czech Republic
- Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- Prague Burn Centre, 3rd Faculty of Medicine, Charles University Prague, Czech Republic
| | - Eva Buršíková
- Institute of Biochemistry and Experimental Oncology, 1st Faculty of Medicine, Charles University Prague, Czech Republic
- Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- Prague Burn Centre, 3rd Faculty of Medicine, Charles University Prague, Czech Republic
| | - Markéta Prchalová
- Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- Prague Burn Centre, 3rd Faculty of Medicine, Charles University Prague, Czech Republic
| | - Zuzana Velenská
- Institute of Pathology 1st Faculty of Medicine, Charles University Prague and General Teaching Hospital, Prague, Czech Republic
| | - David Coufal
- Institute of Computer Science, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | - Jiří Jiráček
- Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| |
Collapse
|
22
|
Mimeault M, Hauke R, Mehta PP, Batra SK. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 2008; 11:981-1011. [PMID: 17979879 PMCID: PMC4401269 DOI: 10.1111/j.1582-4934.2007.00088.x] [Citation(s) in RCA: 168] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Overcoming intrinsic and acquired resistance of cancer stem/progenitor cells to current clinical treatments represents a major challenge in treating and curing the most aggressive and metastatic cancers. This review summarizes recent advances in our understanding of the cellular origin and molecular mechanisms at the basis of cancer initiation and progression as well as the heterogeneity of cancers arising from the malignant transformation of adult stem/progenitor cells. We describe the critical functions provided by several growth factor cascades, including epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), stem cell factor (SCF) receptor (KIT), hedgehog and Wnt/beta-catenin signalling pathways that are frequently activated in cancer progenitor cells and are involved in their sustained growth, survival, invasion and drug resistance. Of therapeutic interest, we also discuss recent progress in the development of new drug combinations to treat the highly aggressive and metastatic cancers including refractory/relapsed leukaemias, melanoma and head and neck, brain, lung, breast, ovary, prostate, pancreas and gastrointestinal cancers which remain incurable in the clinics. The emphasis is on new therapeutic strategies consisting of molecular targeting of distinct oncogenic signalling elements activated in the cancer progenitor cells and their local microenvironment during cancer progression. These new targeted therapies should improve the efficacy of current therapeutic treatments against aggressive cancers, and thereby preventing disease relapse and enhancing patient survival.
Collapse
Affiliation(s)
- M Mimeault
- Department of Biochemistry and Molecular Biology, Eppley Institute of Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA.
| | | | | | | |
Collapse
|
23
|
Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 2007; 14:419-30. [PMID: 18049131 DOI: 10.1097/pap.0b013e3181594733] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Triple negative breast carcinomas (TNBCs) are a group of primary breast tumors with aggressive clinical behavior. Most TNBCs possess a basal phenotype (BP) and show varying degrees of basal cytokeratin and myoepithelial marker expression. The importance of recognizing these tumors came to light largely as the result of gene expression profiling studies that categorized breast cancer into 3 major groups. Two of these groups are defined by their respective expression of estrogen receptor and HER2. TNBCs represent a third group and are defined by negativity for hormone receptors and HER2. TNBCs currently lack effective targeted therapies and are frequently resistant to standard chemotherapeutic regimens. These tumors tend to occur in premenopausal women and members of specific ethnic groups and a subset are associated with heritable BRCA1 mutations. For patients with sporadic TNBCs and BP tumors, BRCA1 dysfunction seems to play a major role in the development and progression of disease. The pathologist's role in the diagnosis and characterization of TNBCs and BP tumors is currently being defined as we are acquiring knowledge of the biologic and genetic underpinnings that drive this heterogeneous group of diseases. This review will provide a historical prospective on TNBCs and tumors that express basal cytokeratins and myoepithelial makers. Additionally, we will discuss the molecular biologic, genetic and pathologic aspects of these tumors. Guidelines will be provided on how to best approach the diagnosis of these cases and on what input pathologists should provide clinicians to help develop optimal therapeutic and preventative strategies against this aggressive group of breast cancers.
Collapse
|
24
|
Duss S, André S, Nicoulaz AL, Fiche M, Bonnefoi H, Brisken C, Iggo RD. An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells. Breast Cancer Res 2007; 9:R38. [PMID: 17573968 PMCID: PMC1929103 DOI: 10.1186/bcr1734] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2007] [Revised: 05/29/2007] [Accepted: 06/15/2007] [Indexed: 11/30/2022] Open
Abstract
Introduction About 70% of breast cancers express oestrogen receptor α (ESR1/ERα) and are oestrogen-dependent for growth. In contrast with the highly proliferative nature of ERα-positive tumour cells, ERα-positive cells in normal breast tissue rarely proliferate. Because ERα expression is rapidly lost when normal human mammary epithelial cells (HMECs) are grown in vitro, breast cancer models derived from HMECs are ERα-negative. Currently only tumour cell lines are available to model ERα-positive disease. To create an ERα-positive breast cancer model, we have forced normal HMECs derived from reduction mammoplasty tissue to express ERα in combination with other relevant breast cancer genes. Methods Candidate genes were selected based on breast cancer microarray data and cloned into lentiviral vectors. Primary HMECs prepared from reduction mammoplasty tissue were infected with lentiviral particles. Infected HMECs were characterised by Western blotting, immunofluorescence microscopy, microarray analysis, growth curves, karyotyping and SNP chip analysis. The tumorigenicity of the modified HMECs was tested after orthotopic injection into the inguinal mammary glands of NOD/SCID mice. Cells were marked with a fluorescent protein to allow visualisation in the fat pad. The growth of the graft was analysed by fluorescence microscopy of the mammary glands and pathological analysis of stained tissue sections. Oestrogen dependence of tumour growth was assessed by treatment with the oestrogen antagonist fulvestrant. Results Microarray analysis of ERα-positive tumours reveals that they commonly overexpress the Polycomb-group gene BMI1. Lentiviral transduction with ERα, BMI1, TERT and MYC allows primary HMECs to be expanded in vitro in an oestrogen-dependent manner. Orthotopic xenografting of these cells into the mammary glands of NOD/SCID mice results in the formation of ERα-positive tumours that metastasise to multiple organs. The cells remain wild type for TP53, diploid and genetically stable. In vivo tumour growth and in vitro proliferation of cells explanted from tumours are dependent on oestrogen. Conclusion We have created a genetically defined model of ERα-positive human breast cancer based on normal HMECs that has the potential to model human oestrogen-dependent breast cancer in a mouse and enables the study of mechanisms involved in tumorigenesis and metastasis.
Collapse
Affiliation(s)
- Stephan Duss
- NCCR Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland
| | - Sylvie André
- NCCR Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland
- St Andrews University Medical School, Bute Medical Building, St Andrews, KY16 9TS, UK
| | - Anne-Laure Nicoulaz
- NCCR Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland
| | - Maryse Fiche
- Lausanne University Hospital, CHUV, CH-1011 Lausanne, Switzerland
| | - Hervé Bonnefoi
- Geneva University Hospitals, 30 Boulevard de la Cluse, CH-1211 Geneva, Switzerland
| | - Cathrin Brisken
- NCCR Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland
- École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
| | - Richard D Iggo
- NCCR Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland
- St Andrews University Medical School, Bute Medical Building, St Andrews, KY16 9TS, UK
| |
Collapse
|
25
|
Abstract
Breast cancer is a hormone-based disease with numerous factors contributing to the lifetime risk of developing the disease. While breast cancer risk is reduced by nearly 50% after one full term pregnancy, women over the age of 25 have a significantly greater risk of developing breast cancer immediately following parturition compared to their nulliparous counterparts. It is widely presumed that the increased risk of developing breast cancer following pregnancy is due to the ability of pregnancy-associated hormones to promote the further proliferation of an initiated target cell population. It is surprising however, that the majority of breast cancers that develop following pregnancy lack appreciable expression of either the estrogen or progesterone receptors. This important observation suggests that if hormones play a part in promoting breast cancer following pregnancy, they may not be doing so through direct binding to hormone receptor molecules expressed by breast cancer cells. To reconcile this conceptual conflict we investigated the hypothesis that steroid hormones promote the outgrowth of ER-negative cancers by influencing host cell types distinct from the breast epithelium itself. We demonstrated that increasing the levels of circulating estrogens is sufficient to promote the formation and progression of ER-negative cancers while, pharmacologically inhibiting estrogen synthesis following pregnancy prevents ER-negative tumor formation. Moreover, we demonstrate that the effects of estrogen act via a systemic increase in host angiogenesis, in part through increased mobilization and recruitment of bone marrow stromal derived cells into sites of angiogenesis and to a growing tumor mass. Taken together, these data suggest that estrogen may promote the growth of ER-negative cancers by acting on cells distinct from the cancer cells to stimulate angiogenesis.
Collapse
Affiliation(s)
- Piyush B Gupta
- Broad Institute of MIT & Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA.
| | | |
Collapse
|
26
|
Abstract
The same dietary component, such as fat or phytochemicals in plant foods, can have an opposite effect on breast cancer risk if exposed in utero through a pregnant mother or at puberty. Dietary exposures during pregnancy often have similar effects on breast cancer risk among mothers and their female offspring. High fat intake and obesity are illustrative examples: excessive pregnancy weight gain that increases high birth weight is associated with increased breast cancer risk among mothers and daughters. High body weight during childhood is inversely linked to later breast cancer risk. The main reason why the age when dietary exposures occur determines their effect on breast cancer risk likely reflects the extensive programming of the mammary gland during fetal life and subsequent reprogramming at puberty and pregnancy. Programming is a series of epigenetic/transcriptional modifications in gene expression that can be influenced by changes in the hormonal environment induced, for example, by diet. Because epigenetic modifications are inherited by daughter cells, they can persist throughout life if they occur in mammary stem cells or uncommitted mammary myoepithelial or luminal progenitor cells. Our results indicate that the estrogen receptor (ER), mitogen-activated protein kinase (MAPK), and the tumor suppressors BRCA1, p53, and caveolin-1 are among the genes affected by diet-induced alterations in programming/reprogramming. Consequently, mammary gland morphology may be altered in a manner that increases or reduces susceptibility to malignant transformation, including an increase/reduction in cell proliferation, differentiation, and survival, or in the number of terminal end buds (TEBs) or pregnancy-induced mammary epithelial cells (PI-MECs) that are the sites where breast cancer is initiated. Thus, dietary exposures during pregnancy and puberty may play an important role in determining later risk by inducing epigenetic changes that modify vulnerability to breast cancer.
Collapse
Affiliation(s)
- Sonia De Assis
- Department of Oncology, Georgetown University, Research Building E407, 3970 Reservoir Road NW, Washington, DC 20057, USA
| | | |
Collapse
|
27
|
Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 2006; 26:711-24. [PMID: 16862183 DOI: 10.1038/sj.onc.1209808] [Citation(s) in RCA: 486] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The transcription factor nuclear factor kappa B (NF-kappaB) is constitutively active in both cancer cells and stromal cells of breast cancer; however, the precise role of activated NF-kappaB in cancer progression is not known. Using parental MCF10A cells and a variant that expresses the myoepithelial marker p63 stably overexpressing the constitutively active p65 subunit of NF-kappaB (MCF10A/p65), we show that NF-kappaB suppresses the expression of epithelial specific genes E-cadherin and desmoplakin and induces the expression of the mesenchymal specific gene vimentin. P65 also suppressed the expression of p63 and the putative breast epithelial progenitor marker cytokeratin 5/6. MCF10A/p65 cells were phenotypically similar to cells undergoing epithelial to mesenchymal transition (EMT). MCF10A/p65 cells failed to form characteristic acini in three-dimensional Matrigel. Analysis of parental and MCF10A/p65 cells for genes previously shown to be involved in EMT revealed elevated expression of ZEB-1 and ZEB-2 in MCF10A/p65 cells compared to parental cells. In transient transfection assays, p65 increased ZEB-1 promoter activity. Furthermore, MCF10A cells overexpressing ZEB-1 showed reduced E-cadherin and p63 expression and displayed an EMT phenotype. The siRNA against ZEB-1 or ZEB-2 reduced the number of viable MCF10A/p65 but not parental cells, suggesting the dependence of MCF10A/p65 cells to ZEB-1 and ZEB-2 for cell cycle progression or survival. MCF10A cells chronically exposed to tumor necrosis factor alpha (TNFalpha), a potent NF-kappaB inducer, also exhibited the EMT-like phenotype and ZEB-1/ZEB-2 induction, both of which were reversed following TNFalpha withdrawal.
Collapse
Affiliation(s)
- H L Chua
- Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA
| | | | | | | | | | | |
Collapse
|
28
|
Manusadzhian VG, Bolshakova TD, Menshikov VV, Dubobes GK. [Mass-spectrometry in combination with paper chromatography for determination of homovanillic acid]. Cancer Res 1974; 70:4624-33. [PMID: 4129519 DOI: 10.1158/0008-5472.can-09-3619] [Citation(s) in RCA: 135] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|